Abstract

Purpose: To evaluate the potential role and cellular mechanism of the CXCR4 antagonist (N15P) derived from the N-terminal of viral macrophage inflammatory protein-II (vMIP-II) on the apoptosis induced by HIV-1 extracellular nef protein in vitro.Method: Peripheral blood mononuclear cells (PBMCs) and Jurkat cells were treated with HIV-1 nef protein alone or together with N15P at different doses and time points. The competitive binding effect of N15P against nef was assessed via radioligand binding assays. Apoptosis was evaluated via terminal deoxynucleotidyl transferase biotin-dUTP nick end labeling (TUNEL) assay. The level of nuclear FOXO3a and phospho-FOXO3a was assessed by Western blotting.Results: The interaction of 125I-nef with Jurkat cells was inhibited by N15P in a dose-dependent manner, with IC50 value of 0.3516 ng/ml. N15P protect against nef protein-induced apoptosis in a timeand concentration- dependent manner. The proapoptotic effect of extracellular nef protein in cells was associated with FOXO3a pathway and the changes in intracellular processes were blocked by N15P in a dose-dependent manner.Conclusion: N15P inhibits the apoptosis of uninfected CD4+ T lymphocytes induced by HIV-1 extracellular nef protein. Therefore, N15P is a potential effective CXCR4 antagonist in the course of HIV and could prevent or delay the onset of AIDS.Keywords: HIV-1, Nef, vMIP-II, Bystander lymphocytes, Apoptosis, FOXO3a, CXCR4 antagonist, Macrophage, Inflammation

Full Text
Paper version not known

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.